Cochrane · systematic review · CD008781
Vigabatrin versus carbamazepine monotherapy for epilepsy
Xiao, Y, Gan, L, Wang, J, et al. · Cochrane Database of Systematic Reviews · 2015 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
4
current version
GRADE rated
4
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 2 · 50%Low 2 · 50%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Show all 2 versionsVGB compared with CBZ monotherapy for epilepsy
Population: patients with epilepsy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Time to treatment withdrawal VGB vs CBZ monotherapy | HR 0.75 [0.52, 1.1] | 1 study · 446 participants | Low Downgraded: imprecision |
Time to achieve 6‐month remission after the first 6 weeks of dose stabilisation from randomisation VGB vs CBZ monotherapy | HR 1.18 [0.89, 1.55] | 1 study · 404 participants | Very low Downgraded: imprecision |
Time to first seizure after randomisation VGB vs CBZ monotherapy | HR 1.57 [1.23, 2.02] | 1 study · 404 participants | Low Downgraded: imprecision |
Adverse events Visual field defects VGB vs CBZ monotherapy | RR 5.37 [0.27, 106.88] | 1 study · 54 participants | Very low Downgraded: risk of bias, imprecision |